Alector to Participate in the Bank of America CNS Therapeutics Conference

Group 1 - Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases [3] - The company will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on December 8, 2025 [1] - Alector's product candidates aim to treat conditions such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia [3] Group 2 - Alector is leveraging genetics, immunology, and neuroscience to advance its therapeutic programs [3] - The company is developing a proprietary blood-brain barrier platform called Alector Brain Carrier (ABC) to enhance therapeutic delivery [3] - Alector's goal is to improve patient outcomes while reducing costs through deeper brain penetration and efficacy at lower doses [3]